Obesity and COVID-19: impact of adiposity and comorbidities / Obesidade e COVID-19: impacto da adiposidade e comorbidades

Authors

  • Ana Paula Lima Leopoldo Brazilian Journals Publicações de Periódicos, São José dos Pinhais, Paraná
  • Suellem Torezani Sales
  • Patrícia Vasconcelos Fontana Gasparini
  • André Soares Leopoldo

DOI:

https://doi.org/10.34117/bjdv.v7i5.30128

Keywords:

COVID-19, caused by the new coronavirus (SARS-CoV-2), reaches pandemic levels and can generate manifestations through asymptomatic processes until severe acute respiratory infection. In this scenario, the disorders associated with overweight and morbiditi

Abstract

COVID-19, caused by the new coronavirus (SARS-CoV-2), reaches pandemic levels and can generate manifestations through asymptomatic processes until severe acute respiratory infection. In this scenario, the disorders associated with overweight and morbidities in patients with COVID-19 need to be clarified. The most evident complications include a restrictive respiratory pattern, but excess abdominal fat may accentuate the ventilatory deficit. The purpose of this article is to present the effects of adiposity and comorbidities in individuals affected by COVID-19, as well as to identify the possible mechanisms involved in the severe course of viral infection. The topics addressed reiterate the role of obesity in COVID-19, since it is considered a risk factor for morbidities such as type 2 diabetes mellitus, cardiovascular and liver diseases, which may aggravate the involvement of the respiratory tract. In this context, the obtaining of anthropometric and metabolic data is crucial to estimate the risk of complications to COVID-19. Several strategies for the treatment of the obese individual, including changes in lifestyle, may generate remarkable impacts on adipose tissue, contributing to a better prognosis in the face of the COVID-19 pandemic.

References

Guo YR, Cao QD, Hong ZS, Tan YY, Chen SD, Jin HJ, et al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status. Mil Med Res. 2020; 7: 11. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7068984/.

Romano M, Ruggiero A, Squeglia F, Maga G, Berisio R. A Structural View of SARS-CoV-2 RNA Replication Machinery: RNA Synthesis, Proofreading and Final Capping. Cells 2020; 9: 1267. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7291026/.

Gao Y, Yan L, Huang Y, Liu F, Zhao Y, Cao L, et al. Structure of the RNA-dependent RNA polymerase from COVID-19 virus. Science 2020; pii: eabb7498. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7164392/.

Zheng YY, Ma YT, Zhang JY, Xie X. COVID-19 and the cardiovascular system. Nat Rev Cardiol 2020; 17: 259-260. Available from: https://www.nature.com/articles/s41569-020-0360-5.

European Centre for Disease Prevention and Control (CDPC). COVID-19. Available from: https://www.ecdc.europa.eu/en/covid-19-pandemic.

Strabelli TMV, Uip DE. COVID-19 and the Heart. Arq Bras Cardiol. 2020; 11: 598-600. Available from: https://www.scielo.br/scielo.php?script=sci_arttext&pid=S0066-782X2020005005205&lng=en&nrm=iso&tlng=en.

Centers for Disease Control and Prevention (CDC). Coronavirus Disease 2019 (COVID-19): Cleaning and Disinfection for Community Facilities. Available from: https://www.cdc.gov/coronavirus/2019-ncov/community/organizations/cleaning-disinfection.html.

Ryan DH, Ravussin E, Heymsfield S. COVID 19 and the Patient with Obesity - The Editors Speak Out. Obesity 2020; 28: 847. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7228389/.

Johns Hopkins University Medicine (JHUM). COVID-19. U.S. Map. Available from: https://coronavirus.jhu.edu/map.html.

Ministério da Saúde (MS) – Secretaria de Vigilância em Saúde. Boletim Epidemiológico Especial. Doença pelo Coronavírus COVID-19. 21-27 de fevereiro de 2021. Available flom: https://www.gov.br/saude/pt-br/media/pdf/2021/marco/05/boletim_epidemiologico_covid_52_final2.pdf.

Carter SJ, Baranauskas MN, Fly AD. Considerations for obesity, vitamin D, and physical activity amidst the COVID-19 pandemic. Obesity 2020; Available from: https://onlinelibrary.wiley.com/doi/10.1002/oby.22838.

Louie JK, Acosta M, Winter K, Jean C, Gavali S, Schechter R, et al. Factors associated with death or hospitalization due to pandemic 2009 influenza A(H1N1) infection in California. JAMA 2009; 302: 1896-1902. Available from: https://jamanetwork.com/journals/jama/fullarticle/184820.

Kassir R. Risk of COVID-19 for patients with obesity. Obes Rev. 2020; 21: e13034. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7235532/.

Ryan PM, Caplice NM. Is Adipose Tissue a Reservoir for Viral Spread, Immune Activation, and Cytokine Amplification in Coronavirus Disease 2019? Obesity (Silver Spring). 2020; 28: 1191-1194. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7264526/.

Honce R, Schultz-Cherry S. Impact of Obesity on Influenza, a virus Pathogenesis, Immune Response, and Evolution. Front Immunol. 2019; 10: 1-15. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6523028/.

Zhang AJ, To KK, Li C, Lau CCY, Poon VKM, Chan CCS, et al. Leptin mediates the pathogenesisi of severe 2009 pandemic influenza A (H1N1) infection associated with cytokine dysregulation in mice with diet-induced obesity. J Infect Dis. 2013; 207: 1270-1280. Available from: https://academic.oup.com/jid/article/207/8/1270/891085.

Dietz W, Santos-Burgoa C. Obesity and its Implications for COVID-19 Mortality. Obesity 2020. doi: 10.1002/oby.22818. Available from: https://onlinelibrary.wiley.com/doi/full/10.1002/oby.22818.

Butler MJ, Barrientos RM. The impact of nutrition on COVID-19 susceptibility and long-term consequences. Brain Behav Immun 2020. pii: S0889-S1591: 30537-7. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7165103/.

Muscogiuri G, Barrea L, Savastano S, Colao A. Nutritional recommendations for CoVID-19 quarantine. Eur J Clin Nutr 2020. Available from: https://www.nature.com/articles/s41430-020-0635-2.

Caussy C, Wallet F, Laville M, Disse E. Obesity is associated with severe forms of COVID-19. Obesity 2020. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7264509/.

Malavazos AE, Corsi Romanelli MM, Bandera F, Iacobellis G. Targeting the Adipose Tissue in COVID-19. Obesity 2020. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7264780/.

Qingxian Cai, Fengjuan Chen, Tao Wang, Fang Luo, Xiaohui Liu, Qikai Wu, et al. Obesity and COVID-19 severity in a designated hospital in Shenzhen, China. Diabetes Care 2020; dc200576. Available from: https://care.diabetesjournals.org/content/43/7/1392.long.

ISDS. Characteristics of COVID-19 patients dying in Italy. Available from: https://www.epicentro.iss.it/en/coronavirus/bollettino/Report-COVID-2019_2_april_2020.pdf

Rogero MM, Calder PC. Obesity, Inflammation, Toll-Like Receptor 4 and Fatty Acids. Nutrients 2018; 10. pii: E432. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5946217/.

Andersen CJ, Murphy KE, Fernandez ML. Impact of Obesity and Metabolic Syndrome on Immunity. Adv Nutr 2016; 7: 66-75. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4717890/.

Dongiovanni P, Anstee QM, Valenti L. Genetic predisposition in NAFLD and NASH: impact on severity of liver disease and response to treatment. Curr Pharm Des 2013; 19: 5219-5238. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3850262/.

Lefere S, Tacke F. Macrophages in obesity and non-alcoholic fatty liver disease: Crosstalk with metabolism. JHEP Reports 2019; 1: 30-43. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7052781/.

Korakas E, Ikonomidis I, Kousathana F, Balampanis K, Kountouri A, Raptis A, et al. Obesity and COVID-19: immune and metabolic derangement as a possible link to adverse clinical outcomes. Am J Physiol Endocrinol Metab 2020; 319: E105-E109. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7322508/.

Hu B, Huang S, Yin L. The cytokine storm and COVID-19. J Med Virol. 2020; 10.1002/jmv.26232. Available from: https://onlinelibrary.wiley.com/doi/full/10.1002/jmv.26232.

Liu J, Li S, Liu J, Liu J, Liang B, Wang X, Wang H, et al. Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients. EBioMedicine 2020; 55: 102763. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7165294/.

Grant WB, Lahore H, McDonnell SL, Baggerly CA, French CB, Aliano JL, et al. Evidence that Vitamin D Supplementation Could Reduce Risk of Influenza and COVID-19 Infections and Deaths. Nutrients 2020; 12. pii: E988. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7231123/

Zakharova I, Klimov L, Kuryaninova V, Nikitina I, Malyavskaya S, Dolbnya S, et al. Vitamin D Insufficiency in Overweight and Obese Children and Adolescents. Front Endocrinol 2019; 10: 103. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6406072/.

International Diabetes Federation (IDF). Available from: https://www.diabetesatlas.org/en/sections/worldwide-toll-of-diabetes.html.

Sociedade Brasileira de Diabetes (SBD). Available from: https://www.diabetes.org.br/.

Sanada H, Yokokawa H, Yoneda M, Yatabe J, Sasaki Yatabe M, Williams SM, et al. High body mass index is an important risk factor for the development of type 2 diabetes. Intern Med 2012; 51: 1821-1826. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3540801/.

World Health Organization. Health topics. Available from: https://www.who.int/health-topics/.

Chait A, den Hartigh LJ. Adipose Tissue Distribution, Inflammation and Its Metabolic Consequences, Including Diabetes and Cardiovascular Disease. Front Cardiovasc Med 2020; 7: 22. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7052117/.

Abdullah A, Peeters A, de Courten M, Stoelwinder J. The magnitude of association between overweight and obesity and the risk of diabetes: a meta-analysis of prospective cohort studies. Diabetes Res Clin Pract 2010; 89: 309-319. Available from: https://www.diabetesresearchclinicalpractice.com/article/S0168-8227(10)00194-4/fulltext.

Centers for Disease Control and Prevention (CDC). Prevalence of overweight and obesity among adults with diagnosed diabetes - United States, 1988-1994 and 1999-2002. MMWR Morb Mortal Wkly Rep 2004; 53: 1066-1068. Available from: https://www.cdc.gov/mmwr/preview/mmwrhtml/mm5345a2.htm.

Gupta R, Ghosh A, Singh AK, Misra A. Clinical considerations for patients with diabetes in times of COVID-19 epidemic. Diabetes Metab Syndr 2020; 14: 211-212. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7102582/.

Casqueiro J, Casqueiro J, Alves C. Infections in patients with diabetes mellitus: A review of pathogenesis. Indian J Endocrinol Metab 2012; 16: S27-S36. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3354930/.

Puig-Domingo M, Marazuela M, Giustina A. COVID-19 and endocrine diseases. A statement from the European Society of Endocrinology. Endocrine 2020; 68: 2-5. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7150529/.

Muniyappa R, Gubbi S. COVID-19 pandemic, coronaviruses, and diabetes mellitus. Am J Physiol Endocrinol Metab 2020; 318: E736-E741. Available from: https://journals.physiology.org/doi/full/10.1152/ajpendo.00124.2020.

Deng SQ, Peng HJ. Characteristics of and Public Health Responses to the Coronavirus Disease 2019 Outbreak in China. J Clin Med 2020; 9. pii: E575. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7074453/.

Finer N, Garnett SP, Bruun JM. COVID-19 and obesity. Clin Obes 2020. doi: 10.1111/cob.12365. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7267455/.

Stefan N, Birkenfeld AL, Schulze MB, Ludwig DS. Obesity and impaired metabolic health in patients with COVID-19. Nat Rev Endocrinol 2020. Available from: https://www.nature.com/articles/s41574-020-0364-6.

Bhatraju PK, Ghassemieh BJ, Nichols M, Kim R, Jerome KR, Nalla AK, et al. Covid-19 in Critically Ill Patients in the Seattle Region - Case Series. N Engl J Med 2020. Available from: https://www.nejm.org/doi/full/10.1056/nejmoa2004500.

Stevens B, Pezzullo L, Verdian L, Tomlinson J, George A, Bacal F. The Economic Burden of Heart Conditions in Brazil. Arq Bras Cardiol 2018; 111: 29-36. Available from: https://www.scielo.br/scielo.php?script=sci_arttext&pid=S0066-782X2018001300029.

Clerkin KJ, Fried JA, Raikhelkar J, Sayer G, Griffin JM, Masoumi A, et al. Coronavirus Disease 2019 (COVID-19) and Cardiovascular Disease. Circulation 2020. Available from: https://www.ahajournals.org/doi/full/10.1161/CIRCULATIONAHA.120.046941.

Akhmerov A, Marbán E. COVID-19 and the Heart. Circ Res 2020; 126: 1443-1455. Available from: https://www.ahajournals.org/doi/full/10.1161/CIRCRESAHA.120.317055.

Vaduganathan M, Vardeny O, Michel T, McMurray JJV, Pfeffer MA, Solomon SD. Renin Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19. N Engl J Med. 2020; 382: 1653-1659. Available from: https://www.nejm.org/doi/full/10.1056/NEJMsr2005760.

Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med 2020; 382: 1708-1720. Available from: https://www.nejm.org/doi/pdf/10.1056/nejmoa2002032.

Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020; 395: 507-513. Available from: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30211-7/fulltext.

Carbone S, Canada JM, Billingsley HE, Siddiqui MS, Elagizi A, Lavie CJ. Obesity paradox in cardiovascular disease: where do we stand? Vasc Health Risk Manag 2019; 15: 89-100. Available from: https://www.researchgate.net/publication/332796076_Obesity_paradox_in_cardiovascular_disease_Where_do_we_stand.

Sattar N, McInnes IB, McMurray JJV. Obesity a Risk Factor for Severe COVID-19 Infection: Multiple Potential Mechanisms. Circulation 2020. Available from: https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.120.047659.

Kalligeros M, Shehadeh F, Mylona EK, Benitez G, Beckwith CG, Chan PA, et al. Association of Obesity with Disease Severity among Patients with COVID-19. Obesity 2020. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7267224/.

Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M, et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol 2020. pii: S0168-8278:30201-4. Available from: https://www.journal-of-hepatology.eu/article/S0168-8278(20)30201-4/fulltext.

Ji D, Qin E, Xu J, Zhang D, Cheng G, Wang Y, Lau G. Non-alcoholic fatty liver diseases in patients with COVID-19: A retrospective study. J Hepatol 2020. pii: S0168-8278: 30206-30213. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7141624/.

Fabbrini E, Mohammed BS, Magkos F, Korenblat KM, Patterson BW, Klein S. Alterations in adipose tissue and hepatic lipid kinetics in obese men and women with nonalcoholic fatty liver disease. Gastroenterology 2008; 134: 424-431. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2705923/.

Donnelly KL, Smith C, Schwarzenberg S, Jessurun J, Boldt MD, Parks EJ. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest 2005; 115: 1343-1351. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1087172/.

Blencowe M, Karunanayake T, Wier J, Hsu N, Yang X. Network Modeling Approaches and Applications to Unravelling Non-Alcoholic Fatty Liver Disease. Genes (Basel). 2019; 10. pii: E966. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6947017/.

Mirea AM, Tack CJ, Chavakis T, Joosten LAB, Toonen EJM. IL-1 Family Cytokine Pathways Underlying NAFLD: Towards New Treatment Strategies. Trends Mol Med 2018; 24: 458-471. Available from: https://www.sciencedirect.com/science/article/abs/pii/S1471491418300510.

Ziemia?ski P, Domienik-Kar?owicz J, Cylke R, Pruszczyk P, Kosieradzki M, Lisik W. High-sensitivity C-reactive protein as a new predictor of the course of nonalcoholic fatty liver disease in patients after bariatric surgery. Pol Arch Intern Med 2019; 129: 556-558. Available from: https://www.mp.pl/paim/issue/article/14827/.

Gacouin A, Locufier M, Uhel F, Letheulle J, Bouju P, Fillatre P, et al. Liver Cirrhosis is Independently Associated With 90-Day Mortality in ARDS Patients. Shock 2016; 45: 16-21. Available from: https://journals.lww.com/shockjournal/Fulltext/2016/01000/Liver_Cirrhosis_is_Independently_Associated_With.4.aspx.

Bangash MN, Patel J, Parekh D. COVID-19 and the liver: little cause for concern. Lancet Gastroenterol Hepatol 2020. pii: S2468-1253(20)30084-4. Available from: https://www.thelancet.com/journals/langas/article/PIIS2468-1253(20)30084-4/fulltext.

Prins GH, Olinga P. Potential implications of COVID-19 in non-alcoholic fatty liver disease. Liver Int 2020. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7264616/.

Channappanavar R, Fehr AR, Vijay R, Mack M, Zhao J, Meyerholz DK, et al. Dysregulated Type I Interferon and Inflammatory Monocyte-Macrophage Responses Cause Lethal Pneumonia in SARS-CoV-Infected Mice. Cell Host Microbe 2016; 19: 181-183. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4752723/.

Hu LL, Wang WJ, Zhu QJ, Yang L. Novel coronavirus pneumonia-related liver injury: etiological analysis and treatment strategy. Zhonghua Gan Zang Bing Za Zhi 2020; 28: 97-99. Available from: https://pubmed.ncbi.nlm.nih.gov/32075364/.

Gao F, Zheng KI, Wang XB, Sun QF, Pan KH, Wang TY. Obesity is a risk factor for greater COVID-19 severity. Diabetes Care. 2020; 43: e72-e74. Available from: https://care.diabetesjournals.org/content/early/2020/05/12/dc20-0682.

Published

2021-06-07

How to Cite

Leopoldo, A. P. L., Sales, S. T., Gasparini, P. V. F., & Leopoldo, A. S. (2021). Obesity and COVID-19: impact of adiposity and comorbidities / Obesidade e COVID-19: impacto da adiposidade e comorbidades. Brazilian Journal of Development, 7(5), 51010–51029. https://doi.org/10.34117/bjdv.v7i5.30128

Issue

Section

Original Papers